Event Participants
Executives
4 Vinita Gupta, Nilesh Gupta, Ramesh Swaminathan, Ravi
Analysts
6 Bino Pathiparampil, Damayanti Kerai, Neha Manpuria, Shyam Srinivasan, Tushar Manudhane, Vivek Agrawal
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Revenue | ₹8,277 crores | Up 32% YoY; record quarter, 16th consecutive quarter of growth |
| EBITDA | ₹2,464 crores | Up 50% YoY from ₹1,641 crores; margin 30.0% vs 26.6%, +340 bps YoY |
| Gross Margin | 74.6% | +330 bps YoY from 71.3%; better product mix, India profitability, cost efficiencies |
| US Sales | $366 million | +30% YoY constant currency; base volume growth offset by mirabegron competition |
| India Sales | ₹2,380 crores | +13.9% YoY; core prescription +15.1% vs IPM +13.5% (1.1x); chronic share 67% |
| Other Developed Markets | ₹1,149 crores | +48% YoY; 14% of revenues (11% in FY26); Visu Pharma consolidation from this quarter |
| Emerging Markets | ₹990 crores | +52% YoY; Brazil +117% YoY in local currency, South Africa, Philippines |
| R&D Spend | ₹608 crores | 7.4% of sales vs 8.1% in Q1 FY26; full year expected ~8% |
| Employee Expenses | ₹1,383 crores | +28% YoY; 16.8% of sales vs 17.6% - annual increments, business growth |
| Manufacturing & Other Expenses | ₹2,341 crores | ~28.5% of sales vs 28.7%; field force expansion, license payments, settlement agreements |
| Effective Tax Rate | 29.0% | Full year expected 27-28% |
| Net Cash | ₹2,831 crores | Down from ₹4,636 crores at Mar-26; Visu Pharma acquisition |
| Operating Working Capital | ₹8,260 crores | 90 days vs 87 days at Mar-26 |
| ROCE | 29.5% | Up from 28.4% at end FY26 |
Geographic & Segment Commentary
US (43% of revenue): Record sales of $366 million (+30% YoY CC), driven by higher base portfolio volumes and tolvaptan growth, partially offset by increased mirabegron competition. Full year expected at $1.1-1.2 billion as additional tolvaptan entrants (Apotex, Teva, possibly a fourth in September) compress pricing from Q2. US expected to return to growth trajectory from FY28, led by complex product pipeline of 50+ launches, 10 exclusive FTFs, 5 biosimilars, and 2-3 505(b)(2) products. Tiotropium share settled at ~38%; albuterol stabilized at ~16% share. Respiratory portfolio represents over 20% of US base business.
India (29% of revenue): Sales of ₹2,380 crores (+13.9% YoY) with core prescription business +15.1% (1.1x IPM). Chronic segment at 67% of mix (target 70% in 5 years). Diabetes segment +31.8% YoY led by human insulin leadership and semaglutide injection launch; vial and oral semaglutide expected H2 FY27. Anti-diabetes and cardiac grew 1.8x and 1.2x category respectively; respiratory lagged at 6.9% vs 11.3% category. Sales force ~11,300, with 80+ product launches planned over coming years.
Europe, Canada, Australia (14% of revenue): Sales of ₹1,149 crores (+48% YoY) with Europe up 83% YoY. Busu Pharma (Visu Pharma) consolidation initiated this quarter. Strategy focuses on complex generics, biosimilars (ranibizumab, aflibercept), and specialty portfolio via Visu Pharma's ophthalmology footprint. Management sees significant headroom, targeting double-digit growth (10-20%) over next 2 years with expanding margins.
Emerging Markets (12% of revenue): Sales of ₹990 crores (+52% YoY) led by Brazil (+117% YoY local currency), South Africa, and Philippines. Brazil driven by dapagliflozin commercialization and empagliflozin launch; semaglutide launch in South Africa later this year. Building diabetes-metabolic franchise across EM.
Company-Specific & Strategic Commentary
Complex Products Strategy: Targeting doubling complex product share in US; 50+ US launches over next 3 years including 10 exclusive FTFs, 5 biosimilars, 2-3 505(b)(2) products; 15+ filings this year including 7+ respiratory. Pipeline includes 60+ injectables and 3 respiratory products in development.
Respiratory Pipeline Progress: DULERA filed; RESPIMAT file this fiscal year; positive pivotal PK on Breo (Ellipta platform), TRELEGY next; levalbuterol green propellant filed in Europe; fluticasone nasal spray Rx approval expected this year, OTC FY28.
Biosimilars & 505(b)(2): Pegfilgrastim launch H2 FY27; biosimilars expected to scale to a couple of hundred million dollars over 3 years across US and Europe. Apixaban 505(b)(2) targeting approval September, commercial quantity January 2027, launch in summer with 10-12 months advantage over generics (FY29 entry); filed from Somerset.
India Innovation Strategy: Target of 1/3 India revenues from novel proprietary products in 10 years; 60-70 innovative product launches over 10 years (3-4 in next 3 years) via in-house development, in-licensing, and NCEs (e.g., Bofanglutide in clinical development); profitability expected similar or better than India business.
Compliance: Received EIRs with VAI status for Ankleshwar and Somerset; Pithampur Unit II responses submitted, remediation on track.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth | High single-digit for FY27 | Reiterated; ex-US organic growth +20% YoY in Q1, US moderating in H2 |
| EBITDA Margin | ~25% for FY27 (vs 30% Q1) | Moderation due to US competitive intensity on tolvaptan/mirabegron; gross margin pressure from competition and geopolitical cost inflation |
| US Sales | $1.1-1.2 billion FY27 | Growth in base business, injectables, pegfilgrastim offset by competition in key products |
| R&D Spend | ~8% of sales FY27 | Continuous focus on complex/specialty platforms |
| Effective Tax Rate | 27-28% FY27 | vs 29% in Q1 |
| India Formulations | Outperform IPM by 1.2-1.3x | Supported by 11,300-person field force and 80+ launches |
| US Growth Trajectory | Return from FY28 | Base of FY27; driven by biosimilars, FTFs, 505(b)(2), respiratory launches |
Risks & Constraints
| Risk | Context |
|---|---|
| US Generic Competition | Tolvaptan facing 3-4 player market from Q2 (Apotex, Teva, potential September entrant) with expected pricing decline; mirabegron already pressuring - full quarter impact from Q2. Management expects US run-rate of $250-280M/quarter over next couple of quarters. |
| Cost Inflation / Geopolitical | Raw material cost increases from geopolitical tensions not fully reflected in Q1 due to carry-forward inventory; will impact gross margins in H2. Management guiding conservatively at 24-25% EBITDA margin range. |
| Pithampur Unit II Remediation | Responses submitted; still under remediation. No timing given for regulatory resolution. |
| Loss-making Adjacent Businesses | Diagnostics, digital, OTC, CDMO businesses collectively dragging EBITDA by ~1-1.5%. Diagnostics expected to break even next year, but near-term margin impact persists. |
| Europe Healthcare Budget Pressure | Germany doubling rebates; all major European markets struggling with drug spend budgets. Some mitigation via biosimilar substitution incentives (France doubling down), but pricing pressure persists across portfolio. |
Q&A Highlights
US Growth Trajectory & FY27 Base
- Question: Is the FY28 growth trajectory on FY27 base of $1.1-1.2 billion in US? (Damayanti Kerai, HSBC)
- Answer: Confirmed - growth comes off the FY27 base (Vinita Gupta).
US Quarterly Run-Rate Step-Down
- Question: Q1 was $366M; guidance implies $250-280M/quarter in Q2-Q4. Is it both top products or conservatism? (Shyam Srinivasan, Goldman)
- Answer: Q1 had no incremental tolvaptan competition; from Q2, Apotex and Teva enter, possibly a fourth in September - expect a 4-player market with pricing decline and share redistribution. Mirabegron sees full quarter impact from Q2. US revenues of $250-280M/quarter over next couple of quarters (Vinita Gupta).
Gross Margin & EBITDA Margin Normalization
- Question: Given Q1 gross margin of 75%, what is normalized gross margin? (Shyam Srinivasan, Goldman)
- Answer: Gross margins will reduce due to tolvaptan realization, competitive intensity, and geopolitical cost increases (inventory carry-forward masked Q1 impact). EBITDA margin guidance of 24-25% reflects a cautious view (Ramesh Swaminathan).
Tolvaptan Market Share Defense
- Question: Can share be defended with additional competition? (Neha Manpuria, BofA)
- Answer: Share decline expected to be slower given specialty pharmacy distribution and REMS program; will still cede some share to new entrants (Vinita Gupta).
Apixaban 505(b)(2) Opportunity
- Question: How large can apixaban 505(b)(2) be? Can it match mirabegron/tolvaptan? (Neha Manpuria, BofA)
- Answer: Potentially yes. Approval goal September, commercial quantities from January 2027, launch in summer with 10-12 months exclusivity before generics enter FY29. Target channels via national accounts. Filed from Somerset (Vinita Gupta).
Biosimilars Scale Over 3 Years
- Question: How big can biosimilars be in US and Europe over 3 years? (Neha Manpuria, BofA)
- Answer: Material opportunity - ramping to a couple of hundred million dollar scale business across US and Europe in 3 years. Pegfilgrastim largest US opportunity; ranibizumab bigger in Europe leveraging Visu Pharma ophthalmology footprint and Sandoz partnerships; aflibercept FY29 (Vinita Gupta).
India Innovation Portfolio Strategy & Profitability
- Question: What's the strategy for 1/3 of India revenues from innovative products? Are in-licensing deals accretive? (Kunal)
- Answer: Three avenues - internal pipeline, in-licensing, and NCEs like Bofanglutide. Allocated capital; cost lower than typical licensing for India-only development. 60-70 innovative launches over 10 years, only 3-4 in next 3 years. Profitability expected similar or better than existing India business (Vinita Gupta, Nilesh Gupta).
Adjacent Businesses EBITDA Drag
- Question: What's the EBITDA margin impact of loss-making adjacencies? (Vivek Agrawal, Citi)
- Answer: About 1-1.5% overall. Diagnostics, digital, OTC, CDMO still loss-making; diagnostics expected to break even next year, digital evolving well. These losses will reduce over time (Ramesh Swaminathan).
Respiratory Platform Development Cycles
- Question: How are DPI/MDI learnings accelerating next wave of respiratory products? (Kunal)
- Answer: Different complexities per platform - Ellipta was most challenging (Breo PK positive, TRELEGY next applying learnings); RESPIMAT was device-related (cleared, filing this year, follow-ons easier); MDI filings significant this year. FDA expediting approvals for products with no competition; Coral Springs manufacturing may aid onshoring review (Vinita Gupta).
Fluticasone Nasal Spray Status
- Question: Which dosages have been filed and approval timeline? (Tushar Manudhane, Motilal Oswal)
- Answer: Both Rx and OTC filed; Rx approval expected this year (FY27), OTC in FY28. Formulation in-house (Somerset), device sourced from manufacturer (Vinita Gupta).
Sustainability of ODM Growth & Margins
- Question: What is sustainable growth for Europe/ODM and margin trajectory? (Saurabh)
- Answer: Double-digit growth expected (10-20% range) over next couple of years; margins expanding with scale and portfolio addition. Small but incremental commercial investments planned for biosimilars and 505(b)(2) in US (Vinita Gupta).
Key Takeaway
Lupin delivered a record Q1 FY27 with revenue of ₹8,277 crores (+32% YoY) and EBITDA of ₹2,464 crores (+50% YoY, 30% margin), marking the 16th consecutive quarter of growth with broad-based expansion across US (+30% CC), India (+13.9%), ODM (+48%) and emerging markets (+52%). Management reiterated FY27 guidance of high single-digit revenue growth and ~25% EBITDA margins, with US expected at $1.1-1.2 billion as tolvaptan and mirabegron competition intensifies from Q2, compressing quarterly US run-rate to $250-280M. The medium-term story rests on a deep complex product pipeline - 50+ US launches over 3 years including 5 biosimilars (pegfilgrastim H2 FY27), 10 exclusive FTFs, and apixaban 505(b)(2) targeting FY28 launch - with US growth resuming from FY28. India's innovation strategy targets 1/3 of revenues from proprietary products within 10 years, while Biosimilar ramp and Visu Pharma's ophthalmology footprint position Europe for sustained double-digit growth. Key watch points include US pricing erosion from competitive entrants, geopolitical cost inflation pressuring gross margins, Pithampur remediation status, and ~1-1.5% EBITDA drag from loss-making adjacent businesses.